Drug Profile
Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma
Alternative Names: ADA 308; ADA 409; Backup; Backup I; Backup II; MDA-308; MDA-409Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Medeia Therapeutics
- Developer Aranda Pharma; Tarrex Biopharma
- Class Antineoplastics; Cytoprotectives; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders; Parkinson's disease; Peripheral ischaemia; Prostate cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in Finland
- 28 Mar 2023 No recent reports of development identified for preclinical development in Prostate-cancer in Finland
- 28 Mar 2023 No recent reports of development identified for research development in Neurodegenerative-disorders in Finland